Abstract Search

ea0044ep97 | (1) | SFEBES2016

Graves’ disease with fluctuating thyroid status and hypothyroidism with positive anti-TSH receptor antibody levels – distinctive autoimmune side-effects following alemtuzumab therapy for multiple sclerosis

Pariani Nadia , Willis Mark , Muller Ilaria , Healy Sarah , Nasser Taha , Jones Joanne , Chatterjee V. Krishna K. , Dayan Colin , Robertson Neil , Coles Alasdair , Moran Carla

Alemtuzumab, a highly effective, newly-licensed, treatment for multiple sclerosis (MS), is notably associated with Graves disease (GD), which reportedly has an indolent course.Methods: Case record review of patients who developed thyroid dysfunction (TD) after alemtuzumab treatment in Cambridge & Cardiff, to determine type, frequency and course of TD.Results: 41.8% (104/249; 81F, 23M) of alemtuzumab-treated patients devel...

0 shares

ePoster

ea0021oc3.5 | Young Endocrinologists prize session | SFEBES2009

A multisystem selenoprotein disorder with a thyroid signature

Schoenmakers Nadia , Schoenmakers Erik , Agostini Maura , Mitchell Catherine , Papp Laura , Rajanayagam Odelia , Padidela Raja , Doffinger Rainer , Luan Jian'an , Lu Jun , Campi Irene , Burton Hannah , Muntoni Francesco , O' Donovan Dominic , Dean Andrew , Warren Anne , Guicheney Pascale , Fitzgerald Rebecca , Coles Alasdair , Gaston Hill , Holmgren Arne , Cooke Marcus S , Halsall David , Wareham Nicholas , Beck-Peccoz Paolo , Ogunko Arthur , Dattani Mehul , Gurnell Mark , Chatterjee Krishna

Selenocysteine insertion sequence-binding protein 2 (SECISBP2) mediates translational incorporation of selenocysteine into 25 known human selenoproteins, including iodothyronine deiodinases. Two unrelated male subjects, aged 36 years (P1) and 3.6 years (P2), exhibited markedly elevated free thyroxine (fT4), normal/low free triiodothyronine (fT3), but normal thyrotropin (TSH) levels, indicating reduced T4 to T3 conversion:<table b...

0 shares

Endocrine Abstracts

Graves’ disease with fluctuating thyroid status and hypothyroidism with positive anti-TSH receptor antibody levels – distinctive autoimmune side-effects following alemtuzumab therapy for multiple sclerosis

A multisystem selenoprotein disorder with a thyroid signature

BiosciAbstracts